8-K - Tonix Pharmaceuticals Holding Corp. - 7.01 / 8.01 / 9.01
站内整理正文
Form 8-K - Current report: SEC Accession No. 0001999371-26-008771
Filing Date: 2026-04-23
Accepted: 2026-04-23 07:11:37
Documents: 17
Period of Report: 2026-04-21
Items: Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Tonix Pharmaceuticals Holding Corp. (Filer) CIK : 0001430306 (see all company filings) EIN. : 261434750 | State of Incorp.: NV | Fiscal Year End: 1231 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)
1 | CURRENT REPORT | tnxp_8k-042226.htm iXBRL | 8-K
2 | PRESS RELEASE OF THE COMPANY, DATED APRIL 22, 2026 | ex99-01.htm | EX-99.01
3 | IN VITRO CHARACTERIZATION OF FULLY HUMAN ANTAGONISTIC ANTI-BTLA MONOCLONAL ANTIB | ex99-02.htm | EX-99.02
4 | PHARMACOKINETICS OF TNX-1700 IN NON-HUMAN PRIMATES AND HUMAN FCRN/SERUM ALBUMIN | ex99-03.htm | EX-99.03